This group where the decline in the PSA value was observed had higher prolactin values than the rest of the patients in the study.
So it is likely that the combination of Casodex and Tamoxifen was required to achieve the decline in PSA value reported by Traveller58.
That's another interesting twist. Were I to go on Casodex I'd want Tamoxifen also to counter gynecomastia, but hadn't thought of Tamoxifen as also possibly reducing PSA. FWIW I looked up Traveller 58 in the members directory. I see that he is in Turkey, which may explain why he is on Casodex in the first place, given it is used as a standard treatment in much Europe. If he's watching this forum at all, I'd like to hear from him.
I see that most of the papers on Pubmed relating to Casodex (bicalutamide) monotherapy are 15 or more years old, which suggests that enthusiasm when it was relatively new has waned since.
I did find this paper from 2014 - a review of 11 studies involving 3060 men. It concludes anti-androgen treatment is less successful in terms of overall survival and slowing clinical progression. However, this paper addresses patients with metastatic recurrence, not patients (like me) with BCR. Also it notes one of the main areas of dissatisfaction of patients with the anti-androgen treatment was breast pain and enlargement, which I believe these days can be minimized with Tamoxifen, and to me, seem less onorous than some of the nasty side effects of Lupron or it's equivalents. /www.ncbi.nlm.nih.gov/pubmed/24979481